公司简介
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1...
关联新闻
- Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low
The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.
- Sionna scraps genetic disorder drug program after trial setback; shares tank
Sionna Therapeutics said on Monday it would stop developing its experimental drug as an addition to standard treatment for a type of genetic disorder after it failed to show a meaningful benefit in ...